SEC Tracker
Get the app
CPIX · XBRL financial data

Cumberland Pharmaceuticals financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (CPIX's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue———————381———166
Revenue from contracts with customers10,0869,3538,4989,8499,08610,43611,71310,8378,29213,6799,1318,801
Cost of goods and services sold1,7661,530*1,5761,7111,3231,976*1,4262,0119892,241*1,934—
Research and development1,9251,265*1,1581,0591,3061,293*1,2951,4681,2531,550*1,458772
General and administrative2,3443,439*2,3682,7572,6753,326*2,4632,8752,5724,037*2,5542,548
Operating income (loss)(1,867)(6,179)(1,869)(1,027)(1,694)(1,842)1,292(747)(1,965)(1,371)(3,129)(3,160)
Interest income9981*976269107*12612713292*7861
Interest expense110179*119126137223*164110110113*861
Income tax expense (benefit)725*111111(57)*66623*44
Net income (loss)(1,049)(6,294)(1,946)(1,086)(1,544)(1,904)1,257(741)(1,941)(1,412)(3,290)(4,276)
Earnings per share, basic USD per share(0.07)(0.44)(0.14)(0.08)(0.11)(0.14)0.08(0.05)(0.13)(0.09)(0.22)(0.29)
Earnings per share, diluted USD per share(0.07)(0.44)(0.14)(0.08)(0.11)(0.14)0.08(0.05)(0.13)(0.09)(0.22)(0.29)
Weighted average shares, basic thousands of shares14,27714,167*14,09814,11814,05313,973*14,94314,96114,95914,560*14,96014,982
Weighted average shares, diluted thousands of shares14,27713,785*14,09814,11814,05313,973*15,26014,96114,95914,249*14,96014,982

Balance sheet

CSV

Fiscal quarters (CPIX's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents18,50818,32218,54817,33617,46517,96415,10816,08715,19711,44511,0073,862
Accounts receivable12,6209,75810,64711,62011,31111,70110,48810,31710,43116,94514,26213,420
Inventory8,6714,6094,3284,3024,5104,0004,0993,2232,9356,2265,45430
Prepaid and other current assets—3,0252,6832,3231,9512,7872,1821,5781,3772,4452,066676
Total current assets41,77035,71436,20635,58135,23636,45231,87731,20529,93937,06032,78933,641
Property and equipment, net377368369337312277299298293265237249
Right-of-use asset6,7116,6746,5216,3666,2086,1777,1777,1257,5708,3447,6197,281
Goodwill914914914914914914914914914914914—
Total assets87,75181,77681,51078,51976,74875,58369,93667,90765,89976,82470,99562,880
Accounts payable10,81814,03813,07612,50812,05813,91413,92813,44713,83218,56816,53719,554
Accrued liabilities—13,597———12,251———12,635—7,519
Current portion of long-term debt—0———5,100———0——
Total current liabilities27,32827,98226,42524,75631,08831,62225,52023,97224,31036,74534,48835,193
Lease liability, non-current5,3895,2965,2005,1004,9974,9404,8294,7144,5964,4724,3444,211
Total liabilities52,09552,51654,32052,48752,27853,03741,59540,22840,09852,28049,69245,773
Accumulated deficit(11,194)(17,488)(19,434)(20,520)(22,064)(23,968)(22,711)(23,452)(25,392)(26,804)(30,094)(34,370)
Total stockholders' equity35,99229,60327,48926,34924,77922,85328,65727,99026,12024,88021,63717,438
Total liabilities and equity87,75181,77681,51078,51976,74875,58369,93667,90765,89976,82470,99562,880
Common shares outstanding (cover page) thousands of shares14,25614,17714,19114,09614,04213,96814,96114,96014,95714,95714,98314,983

Cash flows

CSV

Fiscal quarters (CPIX's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(1,049)(6,294)(1,946)(1,086)(1,544)(1,904)1,257(741)(1,941)(1,412)(3,290)(4,276)
Stock-based compensation83*94*7972*76*75*7481*81*172*10778*
Depreciation and amortization1,246*1,233*1,1511,139*1,116*1,496*1,0321,034*1,038*1,042*1,276(1,205)*
Net cash from operating activities1,237*1,040*(2,137)(856)*476*1,905*3,899844*187*3*387169*
Purchases of property and equipment53*49*427*15*2*4826*24*(0)*038*
Net cash from investing activities(95)*261*(58)(47)*190*(27)*(1,228)286*(691)*(3,073)*(61)(1,926)*
Proceeds from issuing common stock——————4,7160—year only——
Share repurchases202*189*248134*99*98*2467*10*0*610*
Net cash from financing activities(883)*(1,487)*2,422(310)*(537)*(1,378)*(5,526)(151)*(387)*(682)*(763)(5,387)*
Net change in cash259*(186)*227(1,212)*128*499*(2,856)979*(891)*(3,752)*(437)(7,145)*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Cumberland Pharmaceuticals3,862166169*15.0M— 10-QJun 30, 2026
ProMIS Neurosciences53,429not reported(10,385)*9.0M5.1 quarters 10-QJun 30, 2026
Tempest Therapeutics779not reported(2,779)*16.0M0.3 quarters 10-QJun 30, 2026
Rockwell Medical10,519not reported2,080*4.0M— 10-QJun 30, 2026
Champions Oncology4,35815,232(492)13.9M8.0 quarters 10-QJul 31, 2026
Provectus Biopharmaceuticals1,157not reported(358)*420.3M3.2 quarters 10-QJun 30, 2026
OnKure Therapeutics166,502not reported(10,354)*40.5M17.0 quarters 10-QJun 30, 2026
Yarrow Bioscience22,92597(1,992)*2.7M11.5 quarters 10-QJun 30, 2026
Outlook Therapeutics11,242not reported(21,011)*243.4M0.5 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.